O'Shaughnessy Asset Management’s Solid Biosciences SLDB Stock Holding History

O'Shaughnessy Asset Management’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,385	Closed	-$115K	–	2684
2021 Q1	$115K	Buy	1,385 +287	+26%	+$31.8K	﹤0.01%	1139
2020 Q4	$125K	Buy	+1,098	New	+$69.4K	﹤0.01%	999

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

O'Shaughnessy Asset Management's SLDB Position: Q2 2021 in Review

O'Shaughnessy Asset Management sold out of Solid Biosciences (SLDB) in Q2 2021, closing a stake of 1,385 shares — an estimated $115K sold.

O'Shaughnessy Asset Management first reported a position in SLDB in Q4 2020 and held it in 2 quarters. The position peaked at $125K in Q4 2020. 92 funds tracked by Wall St. Rank hold SLDB as of Q2 2021.

O'Shaughnessy Asset Management reported no remaining Solid Biosciences position as of Q2 2021 after selling out during the quarter.
O'Shaughnessy Asset Management sold 1,385 Solid Biosciences shares in Q2 2021, an estimated $115K.
O'Shaughnessy Asset Management first reported a position in Solid Biosciences in Q4 2020 and held it in 2 quarters.
O'Shaughnessy Asset Management's Solid Biosciences position peaked at $125K in Q4 2020.
92 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2021.

Based on O'Shaughnessy Asset Management's 13F filing for Q2 2021, filed 9 Aug 2021.